



Contacts: Tularik Inc.  
Alicia Williams (Investors/Media), 650-825-7322

## **Tularik to Present at the Lehman Brothers Seventh Annual Global Healthcare Conference**

**South San Francisco, Calif. –(Business Wire)** – February 26, 2004-- Tularik Inc. (Nasdaq:TLRK) announced today that Andrew Perlman, M.D., Ph.D., Executive Vice President, will present at the Lehman Brothers Seventh Annual Global Healthcare Conference on Wednesday, March 3, 2004 at 4:15 p.m. Eastern Time at the Loews Miami Beach Hotel in Miami Beach, Florida.

The presentation will be webcast and may be accessed at the Company's website, [www.tularik.com](http://www.tularik.com), under the Investors/Media tab. In addition, an archived version of the webcast will be available on the Company's website for 30 days.

### **About Tularik**

Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. The Company's scientific platform is focused on three therapeutic areas: cancer, immunology and metabolic disease. Tularik is currently conducting a pivotal study of T67 for the treatment of hepatocellular carcinoma (HCC) and Phase 2 clinical trials of T607 for the treatment of gastric cancer and esophageal cancer. T487, for the treatment of psoriasis, and T131, for the treatment of type 2 diabetes, are in Phase 2 clinical trials. T487 for the treatment of rheumatoid arthritis is moving into Phase 2 clinical trials. T71 for the treatment of obesity is in Phase 1 clinical trials. A corporate partner, Eli Lilly and Company, is conducting a Phase 2 clinical trial of an oral Factor Xa inhibitor for the prevention and treatment of thrombotic diseases. For more information, visit Tularik's Internet website at [www.tularik.com](http://www.tularik.com).